Philips-Led PreciseOnco Consortium Secures IHI Funding to Advance Precision Cancer Interventions
Image
SHERIDAN, WYOMING - February 03, 2026 - Royal Philips has announced that the PreciseOnco research consortium, coordinated by Philips, has been awarded EUR 14.9 million in public funding from the European Union's Innovative Health Initiative (IHI) to accelerate the development of next-generation precision cancer treatments. The five-year program brings together advanced medical imaging, robotic guidance, and artificial intelligence to improve the safety, accuracy, and efficiency of minimally invasive cancer therapies. With additional in-kind and partner contributions, the total project budget reaches EUR 23.9 million, underscoring the scale and ambition of the initiative.